Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited filings document foreign-issuer reports furnished on Form 6-K, with exhibits drawn from ASX announcements and corporate notices. The record includes disclosures on annual general meeting presentations and voting results, material-event updates, material agreements, operating and financial results, and governance matters tied to the company's battery materials business.
Capital-structure filings cover applications for quotation of ordinary fully paid securities, securities issued from option exercises or convertible-security conversions, performance rights, and director interest notices. These filings also record shareholder voting matters and formal updates relevant to NOVONIX's ADR and foreign-issuer reporting framework.
NOVONIX Limited filed a Form 6-K detailing the issue of additional ordinary shares on the ASX following the conversion of performance rights. The company is applying for quotation of 31,777 NVX ordinary fully paid shares, issued on 26 March 2026 as new securities in an existing quoted class.
The shares were issued for non-cash consideration linked to the performance rights, with an estimated value of AUD 0.29 per share. After this issuance, the total number of NVX ordinary fully paid shares quoted on ASX is 861,396,932. The company also discloses unquoted securities, including performance rights, options, and convertible notes that remain on issue.
Novonix Limited has filed a Form 6-K as a foreign private issuer for March 2026. The filing primarily furnishes an ASX announcement titled “Nasdaq Notice of Minimum Bid Price Deficiency” dated March 18, 2026, indicating the company is addressing a Nasdaq minimum bid price compliance matter.
Novonix Limited has called its 2026 Annual General Meeting for 15 April 2026 as a hybrid event in Brisbane and online, where shareholders can watch, ask questions and vote virtually or in person.
Key items include receiving the FY25 financial and remuneration reports, advisory approval of the 2025 Remuneration Report, and re-election of directors Admiral Robert Natter and Ronald Edmonds. Shareholders are asked to re-approve the Performance Rights Plan for up to 35,000,000 Performance Rights and to grant CEO Michael O’Kronley 5,862,567 FY26 Performance Rights tied to three-year relative TSR and a 2028 revenue modifier. Resolutions also seek approval for 1,371,566 FY26 Share Rights across Phillips 66 Company and six non-executive directors, and an additional 10% share placement capacity under ASX Listing Rule 7.1A, taking potential placement headroom to 25% if approved.
NOVONIX Ltd’s Chief Financial Officer Robert Buell Long filed an initial ownership report showing his equity-based incentives. The Form 3 lists performance rights that can convert into 1,363,398 ordinary shares expiring in 2028, 2,069,142 shares expiring in 2029, and 1,144,130 shares expiring in 2027, all with a conversion price of $0.0000.
NOVONIX Ltd reported the initial equity holdings of Chief Legal and Risk Officer Kimberly J. Heimert. The filing lists two blocks of performance rights that can convert to ordinary shares at an exercise price of $0.0000 per share.
One block relates to 489,818 underlying ordinary shares with an exercise date on December 31, 2027 and expiration on December 31, 2028. The second block relates to 1,724,285 underlying ordinary shares with an exercise date on December 31, 2028 and expiration on December 31, 2029. The filing does not show any buy or sell transactions, only these derivative holdings.
NOVONIX Ltd Chief Operating Officer Dwayne Arnold Johnson filed an initial ownership report showing he holds several grants of performance rights linked to NOVONIX ordinary shares. These performance rights have a zero exercise price and, if vesting conditions are met, can convert into ordinary shares over multiple future dates.
The holdings include one grant tied to 1,724,285 underlying ordinary shares and another tied to 173,062 underlying shares, with exercise dates at the end of 2028 and 2027, respectively. Additional time-based performance rights cover blocks of 258,883 or 258,884 underlying ordinary shares each, with exercise dates on November 1, 2026, 2027, 2028, and 2029, and expirations generally on November 1, 2030. The filing lists these positions only and does not show any new market purchases or sales.
NOVONIX Ltd filed an initial insider ownership report for Chief Executive Officer Michael O'Kronley. The filing shows he holds performance rights that can be converted into 3,723,971 ordinary shares at an exercise price of $0.0000 per share, with these rights expiring on December 31, 2028. This is a holdings disclosure rather than a new buy or sell transaction.
NOVONIX Ltd director Robert J. Natter has filed a Form 3 reporting his existing ownership of the company’s ordinary shares. The filing shows 230,343 ordinary shares held directly. It also shows indirect ownership through trusts, with 1,365,888 ordinary shares held in a trust where he is trustee and 1,298,758 ordinary shares held in a trust where his spouse is trustee. These entries are reported as holdings, not as new market transactions, and provide a baseline view of his beneficial ownership in NOVONIX.
NOVONIX Ltd director Ronald C. Edmonds has filed an initial Form 3 disclosing his ownership in the company. The filing reports that he directly holds 416,342 ordinary shares as of March 16, 2026. This establishes his starting equity position as a reporting insider under SEC rules.
NOVONIX Ltd director files initial ownership report with no transactions
NOVONIX Ltd director Vaidyanathan Suresh has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The filing does not report any equity transactions or derivative exercises, and shows no derivative positions in the derivative summary section.